# To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

> **NCT06522945** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Multi-resistant Gram-negative Bacteria Cause Infection

## Interventions

- **DRUG:** TQD3524
- **DRUG:** TQD3524
- **DRUG:** TQD3524
- **DRUG:** TQD3524
- **DRUG:** TQD3524
- **DRUG:** TQD3524

## Key facts

- **NCT ID:** NCT06522945
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-24
- **Primary completion:** 2025-12-18
- **Final completion:** 2025-12-18
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06522945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06522945, "To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06522945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*